Neuropsychopharmacology

Antipsychotic dosing regimens, commonly daily or via slow-release compounds, are designed to maintain steady-state plasma concentrations. They are guided by their plasma half-life that is typically in the range of several hours. This schedule contrasts with the slow time course of therapeutic efficacy, which often takes weeks to develop fully. This discrepancy led us to hypothesize that the effects of a single dose of an antipsychotic drug might be detectable well beyond the time window predicted by receptor occupancy. To test this, we administered a single dose of the antipsychotic drug clozapine to mice. We observed long-term behavioral effects and changes to cortical activity patterns up to several days after administration. Specifically, clozapine induced a decorrelation of activity in the dorsal cortex observable up to 9 days post administration. This effect was driven by a genetically and functionally distinct subset of layer 5 intratelencephalic neurons, possibly through a clozapine induced increase in the reliability of long-range inhibitory functional influence that exhibited a similar long-term change. Thus, our findings suggest that longer dosing intervals for antipsychotic drugs warrant clinical exploration.

Nearly one third of women of reproductive age in the United States are prescribed opioids annually; 14% of women fill an opioid prescription during pregnancy, and one in five report misuse. Opioid use during pregnancy has given rise to an increasing population of infants born with gestational opioid exposure. Although substantial clinical work has focused on treating these infants as they experience opioid withdrawal symptoms at the time of birth, notably few studies have examined the effects of gestational opioid exposure on brain development and long-term cognitive function. During typical brain development, endogenous opioids and their receptors are highly expressed by neural progenitor cells, neurons, and glia where they modulate cell proliferation, differentiation, and maturation. Thus, any disruption to the endogenous opioid system during the critical period of brain development may have lasting consequences on brain cell populations and the behaviors they influence. Indeed, opioid-exposed infants have smaller brains than age-matched peers and show significant neurodevelopmental impairment; they also have higher rates of learning disability at school age. To investigate how exposure to exogenous opioids during brain development affects neural maturation in the hippocampus, a brain region critical for learning and memory, our lab has developed a clinically relevant perigestational morphine exposure rat model. The current study reports that perigestational exposure to morphine delays postnatal hippocampal neuronal maturation, alters astrocyte and oligodendrocyte proliferation, and alters expression of brain-derived neurotrophic factor (BDNF), a protein crucial for healthy brain growth. Furthermore, we show that environmental enrichment rescues BDNF deficits, offering evidence for the effectiveness of non-invasive, non-pharmacological intervention for developmental consequences of perigestational opioid exposure.

Cannabis use is an increasingly common therapeutic for a variety of chronic diseases. In addition, people with sleep problems may self-medicate using cannabis products. However, genetic architecture of cannabis use and its shared genetic predispositions with sleep traits has not been systematically examined. We performed a meta-analysis of cannabis use within the All of Us and UK Biobank cohorts, consisting of 152,807 cases and 220,272 controls. Our meta-analysis identified 39 independent loci, including the previously reported CADM2 locus associated with cannabis use and replicating previous work. Additionally our associations include neuronal and sleep-regulating genes such as HTR1A, RAI1, SLC39A8, and NCAM1. Moreover, tissue-specific analyses revealed that the genetic architecture of cannabis use is heavily enriched within the central nervous system and specific brain cell types. In addition, we observed significant positive genetic correlations with clinical insomnia, insomnia-related medication usage, and objectively measured nighttime physical activity, alongside negative correlations with morningness chronotype and daytime activity. Fine-mapping and colocalization analyses identified shared genetic signals between cannabis use and clinical insomnia including a near-perfect colocalization at SLC39A8 and CADM2. Together, these results highlight the shared genetic risk between cannabis use and sleep disorders. Additionally, our findings indicate the importance of investigating the genetic effects of cannabis use as its use becomes more widespread, both recreationally and medicinally.

Background and PurposeIts been reported that illicit drug supplies increasingly contain the 2-adrenergic agonist, xylazine, alongside fentanyl, yet the pharmacological basis for the greater lethality of this combination remains unclear. Prior research has shown that -opioid (Oprm1) receptors, on which fentanyl acts, and 2-adrenergic (Adra2a) receptors, on which xylazine acts, are both expressed within brainstem circuits that govern autonomic control, especially the parabrachial (PB) and Kolliker-Fuse (KF) nuclei that regulate respiration. Thus, we propose that co-activation of these inhibitory receptors and their respective pathways could potentiate or additively suppress respiratory and thermoregulatory function. Experimental ApproachFreely behaving C57BL/6J mice received intraperitoneal injections of either saline, fentanyl, xylazine, or fentanyl-xylazine (F+X) solutions. Continuous recordings of respiration using whole-body plethysmography, sleep/wake state using EEG/EMG and body temperature using both infrared thermography, and telemetry were collected for several hours following injection. RNAscope was used to identify Oprm1 and Adra2a expression within PB and KF nuclei. ResultsFentanyl alone produced dose-dependent respiratory depression that was not associated with body temperature changes, whereas the dose we used of xylazine alone had no effect on either respiration or body temperature. In contrast, F+X induced a markedly prolonged (>5 h) reduction in respiratory rate and profound hypothermia lasting 7-8 h, exceeding the effects of either drug alone. Mortality increased to 58.8% following F+X exposure. RNAscope revealed that both Oprm1 and Adra2a receptors are expressed in PB/KF FoxP2-positive neurons, identifying a plausible substrate for convergent inhibitory signaling. ImplicationsThis manuscript provides the first direct experimental evidence that fentanyl and xylazine may interact through convergent -opioid and 2-adrenergic receptor signaling to produce additive and sustained suppression of respiratory and thermoregulatory function. These findings address a critical mechanistic gap in understanding the disproportionate lethality of fentanyl-xylazine mixtures, an emerging public-health crisis. The work further identifies the PB/KF FoxP2 population as a plausible site of dual-receptor convergence and highlights a previously unrecognized pharmacodynamic interaction with immediate implications for overdose reversal strategies. Given the novelty, mechanistic insight, and translational urgency of these results, rapid dissemination will help accelerate scientific and clinical responses to this evolving threat. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=75 SRC="FIGDIR/small/719036v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@5b54aeorg.highwire.dtl.DTLVardef@148b7dorg.highwire.dtl.DTLVardef@d1ebccorg.highwire.dtl.DTLVardef@1cfa9c8_HPS_FORMAT_FIGEXP M_FIG Possible convergent -opioid (Oprm1) and 2-adrenergic (Adra2a) signaling within parabrachial FoxP2-expressing neurons likely produces additive suppression of respiratory and thermoregulatory drive during fentanyl-xylazine co-exposure. Fentanyl and xylazine engage parallel inhibitory GPCR pathways in Parabrachial/ Kolliker Fuse nucleus (PB/KF) neurons that project to the pre-Botzinger complex (preBotC) to depress respiratory rhythm and to the dorsomedial hypothalamus (DMH) to blunt thermogenic output. Co-activation of these pathways results in sustained bradypnea, profound hypothermia, and reduced survival, providing a possible mechanistic basis for the increased lethality of fentanyl-xylazine mixtures. C_FIG

Psychedelic drugs are emerging as potentially efficacious tools for treating psychiatric conditions and probing the neural basis of consciousness. Although drug administration context is widely believed to shape psychedelic effects, it remains unclear whether it can independently generate placebo and nocebo effects resembling psychedelic experiences and side effects. In a pre-registered experiment, 78 non-clinical participants inhaled inert medical air under placebo and control conditions while completing a time perception task and a resting-state period. In the placebo condition, the gas was presented as nitrous oxide, whereas in the control, it was correctly identified. Placebo administration increased altered states of consciousness, ego dissolution, dissociation, and side effects, but did not significantly impact time perception. Predictive modelling indicated that placebo-induced psychedelic effects were predicted by trait responsiveness to verbal suggestion and absorption. These findings demonstrate that context alone can induce psychedelic effects, with implications for its causal role in psychedelic action.

Prenatal cannabis exposure (PCE) is increasingly prevalent and has been associated with adverse neurodevelopment outcomes, yet its molecular impact on brain reward circuitry remains poorly defined. Here, we investigated transcriptional and epigenomic alterations in the nucleus accumbens (NAc) following prenatal {Delta}9-tetrahydrocannabinol (THC) exposure in a rat model using snRNA-seq and snATAC-seq analyses. PCE markedly suppressed the expression of genes involved in mitochondrial oxidative phosphorylation in the NAc on postnatal day 24 (P24), consistent with impaired mitochondrial respiration capacity. This mitochondrial dysfunction was accompanied by coordinated alterations in ribosomal and proteasomal pathways regulating protein homeostasis in NAc medium spiny neurons (MSNs), indicating coupled disruption of cellular metabolism and neuronal maturation. snATAC-seq analysis revealed altered chromatin accessibility at promoter regions enriched with NRF1 and YY2 binding motifs, highlighting the importance of transcriptional regulation of mitochondrial gene in MSNs after PCE. Moreover, an acute THC challenge in PCE offspring at P24 further exacerbated mitochondrial dysfunction and delayed MSN maturation. Together, these findings define a transcriptional and epigenetic framework through which PCE perturbs mitochondrial function and impairs MSN maturation in the NAc, providing mechanistic insights into how PCE may alter the development of reward circuity.

The nucleus accumbens (NAc) and its excitatory input from the medial prefrontal cortex (mPFC) form a critical circuit underlying drug-induced plasticity associated with addiction-related behaviors. However, baseline differences in excitatory signaling across NAc subcircuits and sex-specific neuroadaptations following opioid self-administration remain poorly understood. Here, we examined synaptic signaling in mPFC-NAc pathways in drug-naive mice and after abstinence from remifentanil self-administration. Under drug-naive conditions, AMPA receptor- mediated glutamatergic signaling was generally elevated in D2 medium spiny neurons (MSNs) of both the NAc core and shell across sexes, while females exhibited greater excitatory signaling in D1 MSNs of the NAc core compared with males. Pathway-specific analyses revealed that prelimbic cortex (PL) inputs to NAc core D2 MSNs displayed enhanced calcium-permeable AMPA receptor (CP-AMPAR) signaling and increased presynaptic release relative to D1 MSNs. Following abstinence from remifentanil self-administration, miniature excitatory postsynaptic current analyses showed increased excitatory drive at D1 MSNs and decreased drive at D2 MSNs, largely restricted to the NAc core. At PL-Core D1 MSN synapses, remifentanil reduced AMPA/NMDA ratios, consistent with increased CP-AMPAR incorporation in males and females, while increasing presynaptic signaling exclusively in males. In contrast, PL-Core D2 MSN synapses showed a reduction in presynaptic signaling across sex, while ostensibly weakening postsynaptic signaling selectively in males through reductions in CP-AMPAR signaling. At infralimbic cortex (IL)-shell inputs, a reduction in AMPAR rectification indices at D1 MSN synapses was produced by remifentanil, while release probability was decreased at D2 MSN synapses in males only. Together, these findings reveal sex- and pathway-specific synaptic adaptations within mPFC-NAc circuits that may be obscured by global measures of excitatory transmission and identify baseline circuit differences that may shape opioid-induced plasticity.

Relapse to opioid use during abstinence is often triggered by drug-associated cues but the persistence of this effect across the lifespan is unknown. Using a rat model, we found that relapse provoked by heroin-predictive discriminative stimuli persisted for over one year of abstinence, suggesting enduring, potentially lifelong opioid relapse vulnerability.

Delirium is an acute, fluctuating brain dysfunction that commonly follows surgery and systemic inflammation, disproportionately affects older adults, and remains difficult to quantify continuously over time and treat pharmacologically. Here, we tested whether the neuroactive steroid zuranolone, a positive allosteric modulator of synaptic and extrasynaptic GABA_A receptors, mitigates delirium-like abnormalities across two complementary murine delirium models, a lipopolysaccharide-induced systemic inflammation (LPS) model and a postoperative delirium (POD) model, primarily in young and aged mice, with selected analyses in super-aged mice. Using continuous EEG with a validated bispectral EEG (BSEEG) metric, we found that zuranolone attenuated delirium-like EEG slowing in the LPS model in young mice in a dose-dependent manner and retained efficacy in aged mice. In the POD model, prophylactic dosing provided limited benefit in young mice, whereas post-surgery treatment reduced postoperative BSEEG elevations. In aged mice, prophylactic dosing suppressed POD-associated BSEEG abnormalities, and in super-aged mice, prophylactic zuranolone improved survival after POD induction. In parallel, zuranolone reduced microglial density and activation markers (IBA1 and CD68 immunoreactivity) at 24 h after POD surgery and after LPS challenge, with effects that were particularly evident in peri-screw site tissue in young POD mice and more broadly distributed across regions in aged mice. Finally, in young mice, zuranolone improved a composite behavioral severity score in the LPS model, whereas behavioral effects in the POD model were modest and domain-specific. Together, these findings support zuranolone as a candidate strategy to reduce delirium-like electrophysiological and neuroimmune abnormalities, with the strongest effects in inflammation-driven and age-vulnerable contexts.

The 7-nicotinic acetylcholine receptor (7nAChR) has driven extensive research over the past three decades for its pro-cognitive potential. It is the leading druggable target for the cognitive deficits associated with schizophrenia and has motivated major pharmaceutical and clinical efforts to ameliorate similar impairments in other neurological disorders, such as Alzheimers disease (AD). Yet, a systematic evaluation of the role played by 7nAChR in cognition, and its mechanistic underpinnings, is still lacking. Here we report that 7nAChRs on principal and inhibitory forebrain neurons are largely inconsequential to mouse behavior, including in domains that are most sensitive to schizophrenia-related cognitive impairments. By contrast, loss of 7nAChR from astrocytes produces profound behavioral alterations that are cognitive domain-specific, are time-of-day dependent, coincide with reduced levels of the N-methyl D-aspartate receptor (NMDAR) co-agonist D-serine, and are fully restored by D-serine supplementation. Further, an 7nAChR partial agonist previously evaluated in Phase III trials for cognitive enhancement in schizophrenia and AD fails to augment behavior in mice lacking astrocytic 7nAChRs. Together, these findings identify astrocytes and D-serine/NMDAR signaling as a central mechanism through which 7nAChR, a major drug target, promotes cognitive behavior.

Only a subset of heroin users develop addiction, characterized by binge-like heroin use and preference for heroin over other rewards, including social rewards. We recently established a rat model of these features. We trained rats to lever-press for social interaction and heroin (or saline, control) infusions and then tested heroin- and social-seeking and heroin-vs.-social choice. During 3-5 abstinence weeks, we used 2-deoxy-2-[{superscript 1}F]fluoro-D-glucose (FDG) PET imaging to assess regional brain metabolic activity at rest (homecage) and during heroin and social seeking. We assessed regional differences in FDG uptake using unbiased voxel-wise analysis and statistical parametric mapping, and correlated FDG uptake with principle-component-analysis-derived addiction severity score incorporating heroin intake, binge-like episodes, and heroin preference. Compared with saline-trained rats, heroin-trained rats showed overall higher FDG uptake across multiple brain regions at rest and during both reward-seeking tests. Comparison of heroin-vs.-social-seeking in heroin-trained rats showed higher uptake in claustrum/lateral striatum and auditory cortex during social seeking. Analysis of individual differences showed that addiction severity was primarily associated with metabolic alterations under resting conditions rather than during heroin- or social-seeking. At rest, higher addiction severity was associated with lower uptake in piriform cortex and higher uptake in ventral hippocampus, whereas during heroin-seeking, addiction severity was associated with lower uptake in post-subiculum and cerebellum. Addiction severity was not associated with differences in social seeking or FDG uptake during social seeking. These findings identify neurometabolic features of social and heroin seeking and heroin addiction vulnerability that can potentially serve as brain biomarkers and targets for neuromodulation. Significance StatementHeroin addiction develops in only a subset of users, yet the determinants of vulnerability versus resilience to addiction remain largely unknown. We combined a rat model capturing key features of heroin addiction, including binge-like heroin intake and preference for heroin over social interaction, with behavioral heroin- and social-seeking assays and longitudinal whole-brain metabolic imaging using FDG-PET. We identified distinct patterns of neurometabolic alterations associated with heroin self-administration and addiction severity at rest and in the context of heroin seeking. In contrast, heroin self-administration and addiction severity were not significantly associated with neurometabolic alterations during social seeking. These findings highlight brain-wide neurometabolic features of vulnerability to heroin addiction that can serve as brain biomarkers and targets for neuromodulation.

Trauma-focused psychotherapies for post-traumatic stress disorder (PTSD) require waking re-engagement with traumatic memories, driving high dropout. We tested whether trauma-linked auditory cues delivered during slow-wave sleep are feasible. Of 13 patients who provided written informed consent, 6 (100% female) completed overnight Sound Exposure during Sleep (SES); none of the adverse events observed during overnight stimulation were judged by the study team to be attributable to the auditory intervention, and slow-wave sleep was preserved. Two sequential protocol versions were used: Version A (n = 2; capped at SUDs 30-40) and a no-ceiling amendment (Version B, n = 4). Post-hoc exploratory analyses (not powered for efficacy) showed Version B reduced subjective distress (mean difference -65.5%, 95% CI -104.2 to -26.7; nominal p = 0.012) and PCL-5 intrusion (-7.0; nominal p = 0.015). Findings are exploratory and require sham-controlled confirmation. Trial registration: jRCT1030230706.

Special Operations Forces (SOF) sustain repeated low-level blast (LLB) exposures; while most remain resilient, a subset develop depression, sleep disruption and reduced wellbeing that threaten readiness. We asked whether sub-concussive LLB chronically injures an insula-centered cortico-striato-thalamic network and whether network architecture explains divergent outcomes. In a mouse model parameterized to SOF blast exposure monitoring data, ninety 3-psi blasts over three weeks produced persistent diffusion and connectivity deficits across insular, striatal, pallidal and thalamic nodes, accompanied by tauopathy, neuroinflammation, vascular amyloid, and durable sleep and metabolic abnormalities. In SOF Soldiers, measures of cumulative LLB exposure predicted right insula-striatal diffusion/neurite disruption and increased depression risk. Interventional multi-mediator modeling showed that right insula-striatal microstructural injury mediated the effect of LLB to increase depression risk, while moderator screening identified features that amplify or buffer this mediation, defining risk and resilience zones. These findings enable precision blast-medicine integrating exposure dose, circuit biomarkers and moderator profiles.

D1-type receptor (D1R)-mediated dopaminergic signaling within the nucleus accumbens shell (NAcSh) is essential for forming adaptive circuit changes that embed persistent memories associated with drug seeking and craving. While D1R is expressed in both NAcSh neurons and astrocytes, the specific contribution of astrocytic D1R to drug-related circuit plasticity remains poorly understood. Here, we demonstrate in mouse NAcSh slices that D1R agonists increase astrocytic Ca2+ activity, an effect that is attenuated by astrocyte-specific D1R knockdown. Furthermore, selective knockdown of astrocytic D1R in the NAcSh prior to cocaine self-administration inhibits cocaine-induced generation of silent synapses, therefore hampering the associated remodeling of NAcSh circuits. Behaviorally, knockdown of NAcSh astrocytic D1R expedites the extinction of cocaine seeking and reduces cue-induced reinstatement. These results identify astrocytic D1R as a fundamental component of NAcSh dopamine signaling during cocaine experience that remodels synaptic connections and neural networks underlying drug seeking and relapse.

Psychedelics show therapeutic potential for treating psychiatric disorders. While studies have emphasized the roles of cortical pyramidal cells, GABAergic neurons also express serotonin receptors and are therefore likely targets of psychedelics. In this study, we determine the effect of psilocybin on the activity dynamics of major GABAergic cell types in the mouse medial frontal cortex. Psilocybin reduces the firing of somatostatin-expressing interneurons, but increases the activity of parvalbumin-expressing interneurons. This cell type-specific response is unlikely to involve vasoactive intestinal peptide-expressing interneurons. Instead, pharmacological blockade and conditional knockout experiments demonstrate that psilocybin acts on the 5-HT1A receptor at SST interneurons, which contributes to the drugs long-term behavioral effects. Collectively, the results reveal that the classic psychedelic psilocybin alters cortical inhibition in a cell type-specific manner.

Metabotropic glutamate 2/3 receptors (mGluR2/3) have been implicated in depression, anxiety, learning, and memory. However, their causal role in reward-related behaviors remains unclear. Here, we examined the effects of intraperitoneal administration of LY341495, a selective mGluR2/3 antagonist, on reward-related behaviors in mice. In a head-fixed temporal conditioning task, mice received a 10% sucrose solution every 10 seconds. After training, mice exhibited anticipatory licking and pupil dilation aligned with expected reward delivery, indicating successful reward prediction. LY341495 dose-dependently reduced licking behavior without disrupting temporal prediction, as normalization analyses revealed reduced gain but preserved timing. LY341495 also induced overall pupil dilation and attenuated reward-proximity pupillary responses. To determine whether reduced licking reflected general motor impairment, we assessed spontaneous locomotion in a freely moving open-field task. LY341495 did not affect locomotor activity or excretion, suggesting intact general motor and autonomic function. To further evaluate orofacial motor function, we measured ultrasonic vocalizations (USVs) during a social interaction task. LY341495 did not significantly alter USVs, indicating preserved mouth-related motor function independent of licking. In contrast, LY341495 dose-dependently reduced food intake in a freely moving feeding task. Moreover, social preference testing revealed that LY341495 reduced social interaction, suggesting impaired processing of non-food rewards. Together, these findings demonstrate that mGluR2/3 signaling regulates reward-seeking behaviors independently of general locomotor or orofacial motor function. These results provide new insights into glutamatergic mechanisms underlying reward processing and may have clinical implications for obesity, eating disorders, and psychiatric conditions involving motivational dysfunction.

Antidepressant efficacy varies widely, yet the circuit-level mechanisms that distinguish treatment responders from non-responders remain poorly understood in humans. Here, we used high-resolution neuroimaging of hippocampal-amygdala networks during an emotional mnemonic discrimination task that taxes hippocampal pattern separation to examine how antidepressant mechanism of action and perceived treatment response shape emotional memory circuitry (N = 117). Participants included individuals taking single-action antidepressants (selective serotonin reuptake inhibitors), multi-action antidepressants (serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, or polypharmacy), and unmedicated controls matched on current depression severity. Antidepressant mechanism and treatment response were associated with distinct patterns of activity in hippocampal subfields (dentate gyrus (DG)/CA3 and CA1) and amygdala subnuclei, including the basolateral amygdala (BLA) and central amygdala (CEA), during emotional mnemonic discrimination. Among non-responders, the relative balance of hippocampal activity differed by antidepressant mechanism: those taking single-action antidepressants showed greater DG/CA3 than CA1 activity, whereas those taking multi-action antidepressants showed the opposite pattern. This suggests mechanistically specific differences in hippocampal computations associated with ineffective treatment. These effects were localized to the anterior hippocampus, with no significant effects observed in posterior regions. In contrast, responders exhibited stronger DG/CA3-BLA coactivation during negative mnemonic discrimination, a pattern absent in non-responders and unmedicated controls. Antidepressant-associated differences in amygdala subnuclei activity persisted beyond current symptom severity, suggesting medication-related modulation of emotional memory circuits rather than effects driven solely by depression severity. These findings provide evidence in humans that antidepressant use is associated with altered hippocampal-amygdala circuitry in a manner that depends on both pharmacological mechanism and treatment efficacy. Identifying circuit-level signatures of treatment response may inform mechanistically guided approaches to antidepressant selection and monitoring.

Abstinence from repeated cocaine exposure is associated with reduced GABA release from striatal medium spiny neurons that express D2 dopamine receptors (D2-MSN) and project to the ventral pallidum (VP). As a consequence, VP principle neuronal activity is increased and drives cocaine seeking. Abstinence from cocaine is also associated with increased expression of enkephalin in D2-MSNs. This study tested the hypothesis that release of enkephalin from D2-MSNs during cocaine abstinence inhibits GABA release from these same neurons and thereby drives VP excitation. To test this hypothesis, we used mice with conditional knockout of Penk, which encodes enkephalin, in D2-MSNs (D2-PenkKO mice). Cocaine abstinence was associated with reduced GABA release from D2-MSNs to the VP in ex vivo striatal slices from control mice, but not from D2-PenkKO mice. Application of exogenous met-enkephalin inhibited GABA release in D2-PenkKO slices but not in cocaine-abstinent controls, because GABA release was already suppressed in control mice. Optogenetically-evoked GABA release from D2-MSNs inhibited VP excitability in saline-abstinent controls and D2-PenkKOs but not in cocaine-abstinent controls. Additionally, cocaine abstinence suppressed spontaneous firing in control VP neurons, potentially due to adaptive depolarization of their action potential threshold. Our data strongly implicate cocaine-induced autocrine release of enkephalin from D2-MSNs as a key mechanism for GABA plasticity that drives increased VP neuron excitability during cocaine abstinence. Significance StatementGABA release from striatal D2 receptor-expressing medium spiny neurons (d2-MSNs) to the ventral pallidum restrains reward seeking. Following abstinence from long-term cocaine intake, however, GABA release becomes suppressed by an opioidergic mechanism, a form of synaptic plasticity implicated in increased cocaine seeking. The identity and source of the opioid peptide mediating this inhibition have remained unclear. Here, we show that enkephalin produced by D2-MSNs acts in an autocrine manner to reduce GABA release from these neurons, thereby disinhibiting downstream ventral pallidum neurons. Our findings identify D2-MSNs as the source and enkephalin as the opioid responsible for this striatal circuit plasticity. More broadly, this suggests a synaptic mechanism by which synthetic opioids may potentiate cocaine seeking and promote opioid-cocaine polysubstance use.

Cannabidiol (CBD) has recently gained significant public acceptance as a safe therapeutic, contributing to increased use during pregnancy. However, little is known about how maternal CBD exposure impacts fetal brain development. Here, we established a preclinical CBD perinatal exposure (CBD-PCE) model to examine the impacts of CBD on astrocyte morphology in the medial prefrontal cortex (mPFC), a brain region critical for working memory and affective behaviors. Astrocytes play critical roles in maintaining ionic/metabolic homeostasis, neurotransmission, and neurovascular coupling in the CNS. They exhibit highly ramified processes with endfeet surrounding synapses, forming tripartite synapses. We quantitatively assessed the impact of CBD-PCE on astrocyte morphology and the composition of tripartite synapses in mPFC using high-resolution three-dimensional (3D) imaging. Our morphometric analyses revealed that CBD-PCE reduced astrocyte density and increased the number of major branches and whole-cell volume in the mPFC of male, but not female, progenies. Using high-magnification 3D analysis, we found that mPFC astrocytes after CBD-PCE exhibited increased neuropil infiltration volume and reduced surface-to-volume ratios in males but not in females. Moreover, the levels of aquaporin-4 (AQP4) and Kir4.1 inwardly rectifying potassium channel, two key components in regulating ionic homeostasis, are elevated on the membranes of male CBD-PCE astrocytes. We also analyzed mPFC tripartite synapses and observed significant increases in thalamocortical tripartite synapse density in both sexes, whereas intracortical excitatory synapses were reduced only in females. Collectively, these findings demonstrate that CBD-PCE induces sex-specific changes in astrocyte morphology and in the composition of tripartite synapses in the mPFC of the progenys brains.

RationaleCholinergic signalling is critical for attentional control and signal detection, yet the contribution of specific acetylcholine receptor (AChR) subtypes remains poorly understood. Although the 7 nicotinic AChR (nAChR) holds promise as a target for cognition-enhancing therapy, clinical findings to date have been inconsistent. ObjectiveTo investigate the effects of putative cognitive enhancing drugs, including those targeting cholinergic transmission and 7 nAChRs on a visual signal detection task (SDT). MethodsMale and female Sprague Dawley rats were trained on an SDT. Cholinergic transmission was probed systemically with nicotinic and muscarinic receptor antagonists (mecamylamine and scopolamine), a cholinesterase inhibitor (galantamine), an M4-AChR positive allosteric modulator (PAM; VU0467154), an 7 nAChR antagonist (MLA), an 7 nAChR PAM (CCMI), and an 7 nAChR partial agonist (SSR-180,711). Dopaminergic transmission was probed using the catechol-O-methyltransferase (COMT) inhibitor, tolcapone. A novel, trial-level signal detection theory-based generalised linear mixed-effects model (SDT-GLMM) was used to index response bias and perceptual sensitivity (d'), the latter reflecting subjects ability to discriminate signal from noise. ResultsMecamylamine profoundly impaired SDT performance across all measures. Galantamine significantly improved d' at moderate doses but not when a distractor was present. MLA uniquely produced dose-dependent improvements in d' that were preserved under distraction. In contrast, positive allosteric modulation and agonism of 7 nAChRs impaired task performance. Scopolamine, VU0467154, and tolcapone had no consistent or interpretable effects on signal detection. ConclusionsThis work demonstrates that 7 nAChR modulation bidirectionally and dose-dependently regulates perceptual sensitivity, irrespective of attentional distraction. These findings have implications for targeted cognitive enhancement in disorders of attention.